Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DenovoDerm phase I for large deep-partial and full-thickness skin defects
NL-OMON44654Phase 1Withdrawn
- Sponsor
- University of Zurich
- Start
- Oct 2015
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DenovoDerm in Deep wound, sponsored by University of Zurich. Primary endpoints: Rate of local infection and Graft take. Planned start Oct 2015; status: withdrawn.
02
Drugs
DenovoDerm
03
Conditions
Deep wound
Beyond the preview
Go deeper on NL-OMON44654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44654.